Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175–80.

CAS  PubMed  Google Scholar 

Sanden SV, Murton M, Bobrowska A, Rahhali N, Sermon J, Rodruigues B, et al. Prevalence of epidermal growth factor receptor exon 20 insertion mutations in a non-small-cell lung cancer in Europe: a pragmatic literature review and meta-analysis. Targ Oncol. 2022;17:153–66.

Google Scholar 

Burnett H, Emich H, Carroll C, Stapelton N, Mahadevia P, Li T. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLoS ONE. 2021;16(3): e0247620.

CAS  PubMed  PubMed Central  Google Scholar 

Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, et al. Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol. 2018;13(10):1560–8.

PubMed  PubMed Central  Google Scholar 

Arcila ME, Nafa K, Chaft JE, Rakhtman N, Lau C, Reva BA, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12(2):220–9.

CAS  PubMed  PubMed Central  Google Scholar 

Viteri S, Minchom A, Bazhenova L, Ou S-HI, Bauml JM, Shell SA, et al. Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets. Mol Oncol. 2023;17(2):230–7.

CAS  PubMed  Google Scholar 

Bazhenova L, Minchom A, Viteri S, Bauml JM, Ou S-HI, Gadgeel SM, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021;162:154–61.

CAS  PubMed  Google Scholar 

Jarantow SW, Bushey BS, Pardinas JF, Boakye K, Lacy ER, Sanders R, et al. Impact of cell-surface antigen expression on target engagement and function of an epidermal growth factor receptor × c-MET bispecific antibody. J Biol Chem. 2015;290(41):24689–704.

CAS  PubMed  PubMed Central  Google Scholar 

Charakidis M, Boyer M. Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer? Transl Lung Cancer Res. 2014;3(6):395–6.

CAS  PubMed  PubMed Central  Google Scholar 

Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH Jr, Blumenschein GR, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013;31(32):4105–14.

CAS  PubMed  PubMed Central  Google Scholar 

Zheng S, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, et al. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody. MAbs. 2016;8(3):551–61.

CAS  PubMed  PubMed Central  Google Scholar 

Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem. 2000;275(12):8806–11.

CAS  PubMed  Google Scholar 

Ortiz-Zapater E, Lee RW, Owen W, Weitsman G, Fruhwirth G, Dunn RG, et al. MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition. PLoS ONE. 2017;12(1): e0170798.

PubMed  PubMed Central  Google Scholar 

Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 2008;99(6):911–22.

CAS  PubMed  PubMed Central  Google Scholar 

Puri N, Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog. 2008;7:9.

PubMed  PubMed Central  Google Scholar 

Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(1):10–9.

Google Scholar 

Passaro A, Jänne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2(4):377–91.

CAS  PubMed  Google Scholar 

Migliore C, Morando E, Ghiso E, Anastasi S, Leoni VP, Apicella M, et al. miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling. EMBO Mol Med. 2018;10:9.

Google Scholar 

Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-mutant NSCLC. Clin Cancer Res. 2020;26(11):2615–25.

CAS  PubMed  Google Scholar 

Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76(13):3942–53.

CAS  PubMed  Google Scholar 

Haura EB, Cho BC, Lee JS, Han J-Y, Lee KH, Sanborn RE, et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37(15):9009.

Google Scholar 

Vijayaraghavan S, Lipfert L, Chevalier K, Bushey BS, Henley B, Lenhart R, et al. Amivantamab (JNJ-61186372), an Fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol Cancer Ther. 2020;19(10):2044–56.

CAS  PubMed  Google Scholar 

Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Giard N, et al. Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39(30):3391–402.

CAS  PubMed  PubMed Central  Google Scholar 

Zhou C, Tang K-J, Cho BC, Liu B, Paz-Ares L, Cheng S, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. 2023;389(22):2039–51.

CAS  PubMed  Google Scholar 

Hwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):698–3715.

Google Scholar 

Gadgeel S, Cho BC, Lu S, Sethi S, Bauml JM, Nguyen D, et al. Amivantamab pluslazertinib vs osimertinib in first-line EGFR mutant advanced NSCLC: longer follow-up of the MARIPOSA study. WCLC. 2024. San Diego

Passaro A, Wang J, Wang Y, Lee S-H, Melosky B, Shih J-Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77–90.

CAS  PubMed  Google Scholar 

Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, et al. Real-world efficacy and safety of amivantamab for EGFR-mutant NSCLC. J Thorac Oncol. 2024;19(3):500–6.

PubMed  Google Scholar 

Shu CA, Goto K, Ohe Y, Besse B, Lee S-H, Wang Y, Griesinger F, et al. Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. J Clin Oncol. 2022;40(16):9006.

Google Scholar 

Park K, Sabari JK, Haura EB, Shu CA, Spira A, Salgia R, et al. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023;178:166–71.

CAS  PubMed  Google Scholar 

Lopes G, Spira AI, Han J-Y, Chioda M, Simoes J, Paz-Ares L, et al. Preventing infusion-related reactions with intravenous amivantamab: Primary results from SKIPPirr, a Phase 2 study. in World Conference on Lung Cancer. 2024. San Diego, CA

Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis M, et al. Subcutaneous versus Intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated NSCLC: primary results from the phase 3 PALOMA-3 study. J Clin Oncol. 2024;42:3593–605.

CAS  PubMed  Google Scholar 

Douglass L, Gustafson B, Subramanian J. Molecular tumor board case series: targeted treatments for cancer and their toxicities: amivantamab-induced linear iga bullous dermatosis. Mol Med. 2023;120(2):151–4.

Google Scholar 

Fabbrocini G, Panariello L, Caro G. Cacciapuoti, S, acneiform rash induced by EGFR inhibitors: review of the literature and new insights. Skin Appendage Disord. 2015;1(1):31–7.

PubMed  PubMed Central  Google Scholar 

Holcmann M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol. 2015;2(4): e1004969.

PubMed  PubMed Central  Google Scholar